Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
Moodys
Baxter
US Department of Justice
Healthtrust
Dow
Cantor Fitzgerald
Covington
McKinsey

Generated: February 21, 2018

DrugPatentWatch Database Preview

MERCK SHARP DOHME Company Profile

« Back to Dashboard

Summary for MERCK SHARP DOHME
International Patents:944
US Patents:52
Tradenames:41
Ingredients:33
NDAs:52

Drugs and US Patents for MERCK SHARP DOHME

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme STEGLUJAN ertugliflozin; sitagliptin phosphate TABLET;ORAL 209805-002 Dec 19, 2017 RX Yes Yes 9,439,901 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme DUTREBIS lamivudine; raltegravir potassium TABLET;ORAL 206510-001 Feb 6, 2015 DISCN No No 7,169,780*PED ➤ Sign Up Y ➤ Sign Up
Merck Sharp Dohme JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-002 Feb 2, 2012 RX Yes No 7,078,381 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme NOXAFIL posaconazole SOLUTION;IV (INFUSION) 205596-001 Mar 13, 2014 RX Yes Yes 9,750,822 ➤ Sign Up Y ➤ Sign Up
Merck Sharp Dohme JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-002 Feb 2, 2012 RX Yes No 6,890,898 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-003 Dec 19, 2017 RX Yes No 8,080,580 ➤ Sign Up Y Y ➤ Sign Up
Merck Sharp Dohme JANUVIA sitagliptin phosphate TABLET;ORAL 021995-003 Oct 16, 2006 RX Yes Yes 7,125,873 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme ISENTRESS HD raltegravir potassium TABLET;ORAL 022145-002 May 26, 2017 RX Yes No 7,754,731*PED ➤ Sign Up Y ➤ Sign Up
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005 RX Yes Yes 6,503,537*PED ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for MERCK SHARP DOHME

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-002 Nov 10, 1998 5,153,197*PED ➤ Sign Up
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 6,677,322*PED ➤ Sign Up
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005 5,687,710*PED ➤ Sign Up
Merck Sharp Dohme COZAAR losartan potassium TABLET;ORAL 020386-001 Apr 14, 1995 5,608,075 ➤ Sign Up
Merck Sharp Dohme PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER famotidine INJECTABLE;INJECTION 020249-001 Feb 18, 1994 4,283,408*PED ➤ Sign Up
Merck Sharp Dohme CLARINEX-D 12 HOUR desloratadine; pseudoephedrine sulfate TABLET, EXTENDED RELEASE;ORAL 021313-001 Feb 1, 2006 7,214,683*PED ➤ Sign Up
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 6,057,307*PED ➤ Sign Up
Merck Sharp Dohme SINEMET carbidopa; levodopa TABLET;ORAL 017555-003 Approved Prior to Jan 1, 1982 3,830,827 ➤ Sign Up
Merck Sharp Dohme JANUVIA sitagliptin phosphate TABLET;ORAL 021995-002 Oct 16, 2006 6,303,661 ➤ Sign Up
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 5,829,434*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 18 mg/mL, 16.7 mL vials ➤ Subscribe 11/24/2015
➤ Subscribe Delayed-release Tablets 100 mg ➤ Subscribe 6/16/2014
➤ Subscribe Injection 1 g/vial ➤ Subscribe 6/20/2013
➤ Subscribe Tablets 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg ➤ Subscribe 11/6/2012
➤ Subscribe Extended-release Tablets 100 mg/1000 mg ➤ Subscribe 10/22/2012
➤ Subscribe Tablets 100 mg/10 mg and 100 mg/40 mg ➤ Subscribe 6/25/2012
➤ Subscribe Tablets 100 mg/10 mg and 100 mg/40 mg ➤ Subscribe 6/19/2012
➤ Subscribe Extended-release Capsules 50 mg/500 mg and 50 mg/1000 mg ➤ Subscribe 3/16/2012
➤ Subscribe Tablets 400 mg ➤ Subscribe 10/12/2011
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2/28/2011
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 10/18/2010
➤ Subscribe Tablets 50 mg/500 mg and 50 mg/1000 mg ➤ Subscribe 10/18/2010
➤ Subscribe Nasal Spray 50 mcg/ Spray ➤ Subscribe 8/7/2009
➤ Subscribe Capsules 140 mg and 180 mg ➤ Subscribe 3/24/2008
➤ Subscribe Tablets 5 mg ➤ Subscribe 6/21/2006
➤ Subscribe Orally Disintegrating Tablets 2.5 mg and 5 mg ➤ Subscribe 6/21/2006
➤ Subscribe Tablets 100 mg/12.5 mL ➤ Subscribe 4/4/2006
➤ Subscribe Topical Solution (Lotion) 0.10% ➤ Subscribe 6/10/2004
➤ Subscribe Tablets 50 mg/12.5 mg and 100 mg/25 mg ➤ Subscribe 5/24/2004
Premature patent expirations for MERCK SHARP DOHME

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for MERCK SHARP DOHME

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,829,530 Method of regulating glucose metabolism, and reagents related thereto ➤ Sign Up
7,674,790 Processes of making and using pharmaceutical formulations of antineoplastic agents ➤ Sign Up
5,693,626 Tetrahydrofuran antifungals ➤ Sign Up
5,710,154 Tetrahydrofuran antifungals ➤ Sign Up
6,132,758 Stabilized antihistamine syrup ➤ Sign Up
8,076,335 Processes of making pharmaceutical formulations of antineoplastic agents ➤ Sign Up
7,157,429 Method of regulating glucose metabolism, and reagents related thereto ➤ Sign Up
9,090,661 Inhibitors of hepatitis C virus replication ➤ Sign Up
7,635,773 Sulfoalkyl ether cyclodextrin compositions ➤ Sign Up
5,714,490 Tetrahydrofuran antifungals ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for MERCK SHARP DOHME Drugs

Supplementary Protection Certificates for MERCK SHARP DOHME Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00037 Denmark ➤ Sign Up PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
2014041 Lithuania ➤ Sign Up PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-024, 2007 03 21 EU/1/07/382/001-024 20070321
C0026 France ➤ Sign Up PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
00705 Netherlands ➤ Sign Up PRODUCT NAME: SITAGLIPTINE; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
0070004 00113 Estonia ➤ Sign Up PRODUCT NAME: SITAGLIPTIIN;REG NO/DATE: K(2007)1362 23.03.2007
2014000122 Germany ➤ Sign Up PRODUCT NAME: SITAGLIPTIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
0328 Netherlands ➤ Sign Up
545 Luxembourg ➤ Sign Up PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0160050 Estonia ➤ Sign Up (93) SZ 65861 01, 01.04.2016 (93) CH 65861 01, 01.04.2016
1506211/02 Switzerland ➤ Sign Up PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Cantor Fitzgerald
Merck
Accenture
Federal Trade Commission
Cipla
Deloitte
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot